Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in metastatic colorectal cancer
NCT02211443Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of sct200 in metastatic colorectal cancer (mCRC), sponsored by Sinocelltech Group Limited. Primary endpoint: Number of participants with SCT200-related adverse events up to 105 days. Status: unknown.
02
Drugs
sct200
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02211443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211443.